Member Info for pck76

Do we know yet if NCYT’s tests pick up this new variant? (I haven’t seen a report in a while, now that I think about it. They used to publish weekly updates)

Thanks Larry. This is very welcome news, we should have hired the professionals ages ago. I don't know why Institutional investors are not included in their remit. I suppose the house brokers should cover that (and I keep thinking they don't do it properly).
Looking at Walbrook's list of clients I think they have great experience in the field which will hopefully be useful to reverse the current momentum

Has anyone tried to estimate how much the SP could increase following a full win against DHSC? What’s our best guess?

I got official confirmation that mr Twigger does indeed represent the defendant, Primer Design. Hopefully a safe pair of hands!!

Good question Kaeren. I always have the impression NCYT's outstanding research capabilities are not matched by an equally good sales department.

Maybe, instead of (or in addition to) doing deals with other companies to distribute their products, we should make deals with big players who have established (and well connected) commercial teams, so they can distribute ours?

Sir_digby do you have a link to that article? I remember reading it on this board but can’t find it anymore.

I don’t buy the hidden agenda theory either. The end of covid-related sales, but more importantly the failure to explain to the market where revenue will come from in the next few years, have determined the situation we’re in.

This is a company that was worth 13p before covid. It has now 100m in the bank, but retains pretty much the same management. No disrespect but we need to recognise the limitations. It’s like being a local football team, promoted overnight to premier league. The opportunity is massive, but we can’t keep playing with the same amateur players; we need to invest in premier league material. DA was not at the right level; probably the others aren’t either.

But with no debt, growing demand for testing and 100m in the bank, the potential to do well is definitely there. A few, targeted changes could completely transform the fortunes and the prospects of the company.

The more I read about the claim, the more I think it’s utter nonsense.

But moving away from NCYT and speaking as a citizen: since when a public body can keep a report on a potentially very dangerous medical device under wraps, just to avoid commercial damage to the company providing the product?

According to the Good Law Project there are 50 companies involved in the VIP Lane for Test and Trace. Surprisingly Primerdesign is one of them

https://twitter.com/goodlawproject/status/1567541971597643778?s=21&t=za7MztIH251NyNk6FTzUQg

There are names such as Innova which one would definitely expect on the list. But PrimerDesign? The treatment we got from DHSC is definitely not the one a VIP would get: contract not renewed, Dispute etc.

Any views?

While I would love to have sold at £11-12, I am still holding for a few reasons:

- I believe the DHSC dispute will be resolved in our favour. And even if that’s not the case, I do not believe for a second DHSC will be able to get the full amount they are asking. IMO worst case scenario is some sort of “shared responsibility” resulting in DHSC not paying the outstanding invoices, but no further cash leaving NCYT.

- NCYT is willing to focus on the most profitable part of the company. I welcome the closure/disposal of lab 21 and microgen, and also the aggressive focus on reducing opex they have mentioned.

- the focus on building a stronger, internal distribution network means more margin and more control of the relationship with clients. The US by the way is a huge market that we have just begun to work on.

- the regulatory landscape will squeeze smaller player out, and given NCYT’s desire to focus on areas not covered by big firms, this hopefully means the company can carve out a nice niche

- R&D capabilities are second to none, and IP protection for our innovation means we can a) protect revenue and b) get tax rebates.

- some of the relationships (WHO for example) are extremely good and could open lots of doors

- the focus on other areas (transplant etc) I am not able to judge but the way they describe them makes it sound promising.

- the focus on POC/near patient settings, with the ability to produce and sell our own machines (Q16/32, and potentially new products too) will definitely present new opportunities. imagine if GPs had Q machines and could test their patients directly at the practice. (To be honest I think NCYT should give the machines for ‘free’ to increase distribution and only charge for tests… but that’s my opinion)

Overall though this has transformed into a long term holding. I would have preferred to make some quick money ?? but I do believe long term this will turn out to be a good investment.

GLA!

Do we *formally* have a bidder? I mean is there a party bound by the takeover code? I was under he impression they had expressed an interest in evaluating a bid but I didn’t realise this formally meant they have to follow the code etc. is that the case?

Bad news this morning. It would be interesting to know why they decided not to progress with it. But of course we'll never know

anyway, given the current share price, it's clear the market thinks even the Aristocrat bid won't go through. And to be fair I'm not too sure I would support it, the company seems to be undervalued at 680.

Unbelievable they’ve only managed to approve 3 products so far. With this speed they are going to clear the backlog in 2025!..

I am trying to decide whether to sell now and get a premium over the Aristocrat bid, or wait for Gopher's counterbid..

So far I'm inclined to wait. Gopher seems a real contender (see what they did with Finalto)... although I don't get why they haven't tried to takeover the entire company at the time they were approaching Finalto. Any views?

@brentw well said. Also, negative comments are picked up by algo trading systems and end up depressing the SP even more.

better link: https://www.lse.co.uk/rns/AQX/aquis-exchange-achieves-record-market-share-bxz85mgbdpe45cc.html

Aquis exchange just rose to a new record market share in July: 6.2%. Thanks to the subscription model there should be sustained momentum going forward (ie clients should give aquis more and more orders as there is no incremental cost)

Aquis Exchange PLC - Aquis Exchange achieves record market share #AQX @aquis_exchange https://www.**********.co.uk/rns/announcement/15b94b30-847b-4d04-9c68-2277f4f67dec #********** undefined

Hi Wilson, thanks for sharing. Do we know how much NCYT makes on each kit?

Do we know whether any of our products are being used there?
(I assume so as NCYt tweeted about this, but it would be nice to get confirmation)

I seriously doubt GM would release any ‘secret’ / market moving info without issuing a contextual RNS. I’d be happy to be proven wrong of course ;) but don’t think this will be the case. I expect the interview to be a standard one where he explains the strategy, outlook etc.